Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Mutations in the p53 tumor suppressor are the most frequently observed genetic alterations in human cancer. The majority of the mutations occur in the core domain which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292), and they result in loss of DNA binding. The crystal structure of a complex containing the core domain of human p53 and a DNA binding site has been determined at 2.2 angstroms resolution and refined to a crystallographic R factor of 20.5 percent. The core domain structure consists of a beta sandwich that serves as a scaffold for two large loops and a loop-sheet-helix motif. The two loops, which are held together in part by a tetrahedrally coordinated zinc atom, and the loop-sheet-helix motif form the DNA binding surface of p53. Residues from the loop-sheet-helix motif interact in the major groove of the DNA, while an arginine from one of the two large loops interacts in the minor groove. The loops and the loop-sheet-helix motif consist of the conserved regions of the core domain and contain the majority of the p53 mutations identified in tumors. The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modification of any of five arginine residues that are hotspots for TP53 mutations in human cancers disables TP53 sequence-specific DNA binding (Cho, et al., 1994).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Cho, et al., 1994
In the citing paper
“Gly-245 in the wild type adopts unusual backbone dihedral angles (1), which are not favored when the residue is replaced by serine.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The crystal structure of p53 core domain shows that the epitope of PAb240, located in strand 7, is inaccessible to antibody binding (1), and at least a partly unfolded form is required to expose the epitope.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The guanidinium group of Arg-249 is salt-bridged to the carboxylate group of Glu-171 in L2 and backbone oxygens of Gly-245 and Met-246 (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“suggesting the structure of p53 core domain in solution is similar to that in crystal structure (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Principles of Nucleic Acid Structure
Saenger, W. (1984) · Springer Advanced Texts in Chemistry · doi:10.1007/978-1-4612-5190-3 · Cited by 4,150
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Research works printed but not linked: 2
- SACK, J. S., JOURNAL OF MOLECULAR GRAPHICS 6: 224 (1988).
- TONRUD, D.E., ACTA CRYSTALLOGR A 43: 489 (1987).
Cited by
Items 501–600 of 2,517
p53 phosphorylation: Biochemical and functional consequences
Milczarek, G. J., Martinez, J. D., & Bowden, G. T. (1996) · Life Sciences · doi:10.1016/s0024-3205(96)00479-1 · Cited by 109
Glutamine Metabolism Regulates the Pluripotency Transcription Factor OCT4
Marsboom, G., Zhang, G., Pohl-Avila, N. M., Zhang, Y., Yang, Y., Kang, H., Hao, B., Brunengraber, H., Malik, A. B., & Rehman, J. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.089 · Cited by 106
“For example, the DNA binding domain of p53 contains several cysteines that were shown by X-ray crystallography to electrostatically interact with a Zinc atom (Cho et al., 1994).”
BackgroundGu, J., Zhou, Y., Huang, L., Ou, W., Wu, J., Li, S., Xu, J., Feng, J., & Liu, B. (2016) · Molecular and Clinical Oncology · doi:10.3892/mco.2016.1057 · Cited by 89
Regulation of DNA Binding of p53 by its C-terminal Domain
Weinberg, R. L., Freund, S. M. V., Veprintsev, D. B., Bycroft, M., & Fersht, A. R. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.07.042 · Cited by 97
Expression of glypican 3(GPC3) in embryonal tumors
Saikali, Z., & Sinnett, D. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000920)89:5<418::aid-ijc4>3.0.co;2-i · Cited by 99
RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53
Sohr, S., & Engeland, K. (2008) · Cell Cycle · doi:10.4161/cc.7.21.7014 · Cited by 99
Identification of p53 Sequence Elements That Are Required for MDM2-Mediated Nuclear Export
Gu, J., Nie, L., Wiederschain, D., & Yuan, Z.-M. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.24.8533-8546.2001 · Cited by 100
“sheet-helix conformation, as revealed by the crystallographic study (4).”
BackgroundPearson, G. D., & Merrill, G. F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.10.5431 · Cited by 99
PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa
Saha, M. N., Jiang, H., Yang, Y., Reece, D., & Chang, H. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1166 · Cited by 91
Design of a molecular support for cryo-EM structure determination
Martin, T. G., Bharat, T. A. M., Joerger, A. C., Bai, X.-C., Praetorius, F., Fersht, A. R., Dietz, H., & Scheres, S. H. W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612720113 · Cited by 98
Laptenko, O., Beckerman, R., Freulich, E., & Prives, C. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105680108 · Cited by 99
Parks, D. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.6.1289 · Cited by 99
Maiyar, A. C., Phu, P. T., Huang, A. J. Y., & Firestone, G. L. (1997) · Molecular Endocrinology · doi:10.1210/me.11.3.312 · Cited by 107
Clinical Relevance of Gain-Of-Function Mutations of p53 in High-Grade Serous Ovarian Carcinoma
Kang, H. J., Chun, S., Kim, K.-R., Sohn, I., & Sung, C. O. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072609 · Cited by 106
“There are several hotspot mutation sites in p53, such as R175, G245, R248, R249, R273, and R282, which are frequently mutated in cancer [3,11].”
BackgroundNatan, E., Baloglu, C., Pagel, K., Freund, S. M. V., Morgner, N., Robinson, C. V., Fersht, A. R., & Joerger, A. C. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.03.047 · Cited by 98
Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer
Abduljabbar, R. F., Negm, O. H., Lai, C., Jerjees, D. A., Al-kaabi, M. M., Hamed, M. R., Tighe, P. J., Buluwela, L., Mukherjee, A., Green, A. R., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3335-1 · Cited by 111
“Data on a large panel of relevant biomarkers including ER, PgR, HER2, cytokeratins (CK) and markers downstream of ER [27–37] were available, and correlations with those biological features were also investigated.”
Telomerase in human development and cancer
Shay, J. W. (1997) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199711)173:2<266::aid-jcp33>3.0.co;2-b · Cited by 141
Mineta, H., Borg, Å., Dictor, M. R., Wahlberg, P., Åkervall, J., & Wennerberg, J. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.632 · Cited by 104
p53 abnormalities in splenic lymphoma with villous lymphocytes
Gruszka, A., Hamoudi, R., Matutes, E., et al. (2001) · Blood · doi:10.1182/blood.v97.11.3552 · Cited by 98
Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma
Herrero, A., Rojas, E., Misiewicz-Krzeminska, I., Krzeminski, P., & Gutiérrez, N. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122003 · Cited by 98
“In all types of human cancers, the missense TP53 mutations have been detected predominantly in 6 hotspot residues located within the DNA-binding domain (residues R175, G245, R248, R249, R273, and R282) [26,27].”
BackgroundTargeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors
Li, H., Zhang, J., TONG, J. H. M., Chan, A. W. H., Yu, J. Q., Kang, W., & To, K. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235999 · Cited by 114
“The protein was actually regarded as an oncogene at that time, as many tumors produce abundant levels of this protein—a phenomenon that was not observed in normal tissue, and ectopic expression of newly cloned TP53 cDNA was shown to cooperate with oncogenic Ras to transform primary cells in culture [8–10].”
BackgroundInfluentialCRINEPT-TROSY NMR reveals p53 core domain bound in an unfolded form to the chaperone Hsp90
Rüdiger, S., Freund, S. M. V., Veprintsev, D. B., & Fersht, A. R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132393699 · Cited by 97
Structure of the human p53 core domain in the absence of DNA
Wang, Y., Rosengarth, A., & Luecke, H. (2007) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444906048499 · Cited by 96
“However, careful analysis of the ’ and angles of Gly245 in the Ramachandran plot (both around 120 ) suggests that no other amino acid can be accommodated at this position without distorting the main chain and thus the secondary structure (Cho et al., 1994).”
BackgroundMethodInfluentialRegulation of Mutant p53 Temperature-sensitive DNA Binding
Friedlander, P., Legros, Y., Soussi, T., & Prives, C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.41.25468 · Cited by 95
Berns, E., van Staveren, I., Look, M., Smid, M., Klijn, J., & Foekens, J. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.187 · Cited by 96
Pin1-Induced Proline Isomerization in Cytosolic p53 Mediates BAX Activation and Apoptosis
Follis, A. V., Llambi, F., Merritt, P., Chipuk, J. E., Green, D. R., & Kriwacki, R. W. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.06.029 · Cited by 96
“…overlapped with that exploited by BCL-xL, a structural homolog of BAX, to bind p53-DBD; correspondingly, BAX induced CSPs in NMR spectra of 15N-p53- DBD similar to those induced by BCL-xL (Petros et al., 2004), affecting residues in the p53/DNA interface (Cho et al., 1994) (Figures 3C and 3D).”
Storer, R. D., Kraynak, A. R., McKelvey, T. W., Elia, M. C., Goodrow, T. L., & DeLuca, J. G. (1997) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(96)00227-8 · Cited by 95
Arbely, E., Natan, E., Brandt, T., Allen, M. D., Veprintsev, D. B., Robinson, C. V., Chin, J. W., Joerger, A. C., & Fersht, A. R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105028108 · Cited by 96
“The structure was solved by molecular replacement using PHASER (39) with the chain A of PDB ID code 1TSR (40) as a search model.”
MethodIsolation of Temperature-sensitive p53 Mutations from a Comprehensive Missense Mutation Library
Shiraishi, K., Kato, S., Han, S.-Y., Liu, W., Otsuka, K., Sakayori, M., Ishida, T., Takeda, M., Kanamaru, R., Ohuchi, N., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310815200 · Cited by 96
Chrisanthar, R., Knappskog, S., Løkkevik, E., Anker, G. B., Østenstad, B., Lundgren, S., Berge, E. O., Risberg, T., Mjaaland, I., Mæhle, L., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003062 · Cited by 103
“Previously, our group reported mutations in the zink-binding domains L2 (codons 163–195) and L3 (codons 236–251) of p53 critical to DNA binding [12] to be associated with but not fully predictive for resistance to chemotherapy with a low-dose weekly anthracycline [13] or a mitomycin plus 5-fluoro-uracil containing [14…”
BackgroundThe HIRAN Domain and Recruitment of Chromatin Remodeling and Repair activities to Damaged DNA
Iyer, L. M., Babu, M., & Aravind, L. (2006) · Cell Cycle · doi:10.4161/cc.5.7.2629 · Cited by 96
Dell, G., & Gaston, K. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000827 · Cited by 115
Zeng, X., Li, X., Miller, A., Yuan, Z.-M., Yuan, W., Kwok, R. P. S., Goodman, R. H., & Lu, H. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.4.1299-1310.2000 · Cited by 101
“This activity is contributed by three main domains of this protein: the N-terminal transactivation domain (amino acids [aa] 1 to 45) (21, 67), the central sequence-specific DNA binding domain (aa 113 to 290) (6, 12, 66, 80), and the C-terminal regulatory region (30).”
BackgroundThe functional domains in p53 family proteins exhibit both common and distinct properties
Harms, K. L., & Chen, X. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401904 · Cited by 102
Core domain interactions in full-length p53 in solution
Veprintsev, D. B., Freund, S. M. V., Andreeva, A., Rutledge, S. E., Tidow, H., Cañadillas, J. M. P., Blair, C. M., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511130103 · Cited by 95
p53 at the crossroads between cancer and neurodegeneration
Lanni, C., Racchi, M., Memo, M., Govoni, S., & Uberti, D. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.02.034 · Cited by 95
Hansen, S., Hupp, T. R., & Lane, D. P. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.7.3917 · Cited by 94
“Co-crystallization of the core domain with a DNA duplex containing a half consensus site revealed the critical amino acids for DNA binding (Cho et al., 1994).”
BackgroundCell fate regulation governed by p53: Friends or reversible foes in cancer therapy
Song, B., Yang, P., & Zhang, S. (2024) · 癌症:英文版 · doi:10.1002/cac2.12520 · Cited by 107
Yoon, H., Liyanarachchi, S., Wright, F. A., Davuluri, R., Lockman, J. C., de la Chapelle, A., & Pellegata, N. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242597299 · Cited by 94
Wu, L., Ma, C. A., Zhao, Y., & Jain, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.174755 · Cited by 93
Retinoid X receptor alpha forms tetramers in solution.
Kersten, S., Dk, K., Chambon, P., Gronemeyer, H., & Noy, N. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8645 · Cited by 94
A global suppressor motif for p53 cancer mutants
Baroni, T. E., Wang, T., Qian, H., Dearth, L. R., Truong, L. N., Zeng, J., Denes, A. E., Chen, S. W., & Brachmann, R. K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401162101 · Cited by 93
Terakawa, T., Kenzaki, H., & Takada, S. (2012) · Journal of the American Chemical Society · doi:10.1021/ja305369u · Cited by 95
p53 and IGFBP-3: Apoptosis and Cancer Protection
Grimberg, A. (2000) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2000.3008 · Cited by 105
Chk2 regulates irradiation-induced, p53-mediated apoptosis in Drosophila
Peters, M., DeLuca, C., Hirao, A., Stambolic, V., Potter, J., Zhou, L., Liepa, J., Snow, B., Arya, S., Wong, J., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172382899 · Cited by 94
Ubiquitin, E6-AP, and Their Role in p53 Inactivation
Scheffner, M. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00003-5 · Cited by 111
Budinsky, A. C., Brodowicz, T., Wiltschke, C., Czerwenka, K. F., Michl, I., Krainer, M., & Zielinski, C. C. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970611)71:6<1086::aid-ijc27>3.0.co;2-a · Cited by 32
Mutant p53: One, No One, and One Hundred Thousand
Walerych, D., Lisek, K., & Sal, G. D. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00289 · Cited by 100
“org proper folding of the core domain of p53, thus depriving it of the ability to bind the DNA and transactivate its target genes, while the latter group is composed of mutations in residues that are responsible for directly binding DNA, with a near-native core domain structure (10, 11).”
BackgroundHeterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?
Monti, P., Menichini, P., Speciale, A., Cutrona, G., Fais, F., Taìana, E., Neri, A., Bomben, R., Gentile, M., Gattei, V., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.593383 · Cited by 107
Metallothionein: A multifunctional protein from toxicity to cancer
Theocharis, S. E., Margeli, A. P., & Koutselinis, A. S. (2003) · The International Journal of Biological Markers · doi:10.5301/jbm.2008.196 · Cited by 92
Oligomerization of BAK by p53 Utilizes Conserved Residues of the p53 DNA Binding Domain
Pietsch, E. C., Perchiniak, E., Canutescu, A. A., Wang, G., Dunbrack, R. L., & Murphy, M. E. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710539200 · Cited by 92
Health and Cellular Impacts of Air Pollutants: From Cytoprotection to Cytotoxicity
Andréau, K., Leroux, M., & Bouharrour, A. (2012) · Biochemistry Research International · doi:10.1155/2012/493894 · Cited by 101
“Under apoptotic conditions, zinc is also able to increase p53 expression and function probably by stabilizing this protein which contains a tightly bound zinc atom necessary for its DNA binding activity [114, 115].”
BackgroundConsiderations on the folding topology and evolutionary origin of cadherin domains.
Shapiro, L. S., Kwong, P. D., Fannon, A. M., Colman, D., & Hendrickson, W. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.6793 · Cited by 93
Mayer, S., Rüdiger, S., Ang, H. C., Joerger, A. C., & Fersht, A. R. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.06.044 · Cited by 92
Liu, S.-G., Cao, W., Yu, L., Zheng, W., Li, L., Fan, C., & Chen, T. (2013) · Dalton Transactions · doi:10.1039/c3dt33077j · Cited by 97
Bauer, M. R., Jones, R. N., Tareque, R. K., Springett, B., Dingler, F. A., Verduci, L., Patel, K. J., Fersht, A. R., Joerger, A. C., & Spencer, J. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0181 · Cited by 90
A p53-type response element in the GDF15 promoter confers high specificity for p53 activation
Osada, M., Park, H. L., Park, M. J., Liu, J.-W., Wu, G., Trink, B., & Sidransky, D. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.01.089 · Cited by 94
Crystal structure of a p53 core tetramer bound to DNA
Malecka, K. A., Ho, W. C., & Marmorstein, R. (2009) · Oncogene · doi:10.1038/onc.2008.400 · Cited by 89
“This described interface is also consistent with earlier studies implicating specific residues for dimer–dimer interactions (Cho et al., 1994; McClure and Lee, 1998; Ho et al., 2006; Pan and Nussinov, 2007, 2008).”
BackgroundMethodResultInfluentialStoichiometric Phosphorylation of Human p53 at Ser315Stimulates p53-dependent Transcription
Blaydes, J. P., Luciani, M. G., Pospisilova, S., Ball, H. M.-L., Vojtesek, B., & Hupp, T. R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m003485200 · Cited by 90
A transgenic mouse model for mammary carcinogenesis
Li, B., Murphy, K. L., Laucirica, R., Kittrell, F. S., Medina, D., & Rosen, J. M. (1998) · Oncogene · doi:10.1038/sj.onc.1201621 · Cited by 89
“Certain missense mutations of p53 create a unique conformation (Cho et al., 1994) that may facilitate interactions with other proteins by creating a novel interaction site or by disrupting interactions with other cellular proteins that normally serve to block aberrant p53-involved protein-protein…”
BackgroundInfluentialClinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers
Tuna, M., Ju, Z., Yoshihara, K., Amos, C. I., Tanyi, J. L., & Mills, G. B. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0654-8 · Cited by 104
Nagaich, A. K., Appella, E., & Harrington, R. E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.23.14842 · Cited by 89
Kelley, M. L., Winge, P., Heaney, J. D., Stephens, R. E., Farrell, J. H., Beneden, R. J. V., Reinisch, C. L., Lesser, M. P., & Walker, C. W. (2001) · Oncogene · doi:10.1038/sj.onc.1204144 · Cited by 101
“The DBDs of Hsp53 contain 80 ± 90% of the known mutations that have been described in a wide variety of human cancers (Cho et al., 1994; Greenblatt et al., 1994).”
BackgroundStructure–based rescue of common tumor–derived p53 mutants
Wieczorek, A. M., Waterman, J. L. F., Waterman, M. J. F., & Halazonetis, T. D. (1996) · Nature Medicine · doi:10.1038/nm1096-1143 · Cited by 88
Identification of an additional negative regulatory region for p53 sequence-specific DNA binding
Müller-Tiemann, B. F., Halazonetis, T. D., & Elting, J. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6079 · Cited by 89
Dissociation of the recombination control and the sequence-specific transactivation function of P53
Dudenhöffer, C., Kurth, M., Janus, F., Deppert, W., & Wiesmüller, L. (1999) · Oncogene · doi:10.1038/sj.onc.1202964 · Cited by 96
“Beyond a partial juxtaposition of domains participating in both activities, namely DNA-binding via the core and regulation via the C-terminal end (Cho et al., 1994; Jayaraman and Prives, 1995; Lee et al., 1995; Bayle et al., 1995; Reed et al., 1995; Selivanova et al., 1996), we also discovered di…”
BackgroundInfluentialSchlereth, K., Heyl, C., Krampitz, A.-M., Mernberger, M., Finkernagel, F., Scharfe, M., Jarek, M., Leich, E., Rosenwald, A., & Stiewe, T. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003726 · Cited by 87
“On the DNA side, the interaction of p53 with a certain DNA motif is largely influenced by the central CWWG sequence even though the WW dinucleotide is not directly contacted by p53 [15,19,20].”
BackgroundMolecular interplay between mutant p53 proteins and autophagy in cancer cells
Cordani, M., Butera, G., Pacchiana, R., & Donadelli, M. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.11.003 · Cited by 97
Microbial-based therapy of cancer: Current progress and future prospects
Bernardes, N., Seruca, R., Chakrabarty, A. M., & Fialho, A. M. (2010) · Bioengineered Bugs · doi:10.4161/bbug.1.3.10903 · Cited by 92
Dynamic interactions of p53 with DNA in solution by time-lapse atomic force microscopy
Jiao, Y., Cherny, D. I., Heim, G., Jovin, T. M., & Schäffer, T. E. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.5129 · Cited by 95
Vautier, G., Bomford, A. B., Portmann, B. C., Metivier, E. M., Williams, R. L., & Ryder, S. D. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70562-7 · Cited by 93
Towards improving the utility of fine‐needle aspiration biopsy for the diagnosis of thyroid tumours
Haugen, B. R., Woodmansee, W. W., & McDermott, M. T. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01500.x · Cited by 87
“Suspected p53 mutations have been detected in up to 50% of all human malignancies, making them among the most common of all cancer-causing gene alterations (Frebourg & Friend, 1992; Harris & Hollstein, 1993; Cho et al. , 1994; Greenblatt et al. , 1994; Hooper, 1994).”
BackgroundCrystal Structure of the Mouse p53 Core DNA-binding Domain at 2.7 Å Resolution
Zhao, K., Chai, X., Johnston, K., Clements, A., & Marmorstein, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011644200 · Cited by 88
Flexibility: the key to p53 function?
Milner, J. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)88954-9 · Cited by 88
Doyle, B., Morton, J. P., Delaney, D. W., Ridgway, R. A., Wilkins, J. A., & Sansom, O. J. (2010) · The Journal of Pathology · doi:10.1002/path.2748 · Cited by 87
Klein, C., Planker, E., Diercks, T., Kessler, H., Künkele, K.-P., Lang, K., Hansen, S., & Schwaiger, M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107516200 · Cited by 75
Trbušek, M., Šmardová, J., Malčíková, J., Šebejová, L., Dobes, P., Svitáková, M., Vranová, V., Mráz, M., Francová, H. S., Doubek, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7872 · Cited by 93
Mosleh-Shirazi, S., Kasaee, S. R., Dehghani, F., Kamyab, H., Kirpichnikova, I., Chelliapan, S., Firuzyar, T., Akhtari, M. R., & Amani, A. M. (2022) · Ceramics International · doi:10.1016/j.ceramint.2022.11.329 · Cited by 86
Formation of Disulfide Bond in p53 Correlates with Inhibition of DNA Binding and Tetramerization
Sun, X. Z., Vinci, C., Makmura, L., Han, S., Tran, D., Nguyen, J., Hamann, M., Grazziani, S., Sheppard, S., Gutova, M., et al. (2003) · Antioxidants & Redox Signaling · doi:10.1089/152308603770310338 · Cited by 86
“The cysteine thiol groups predicted to be exposed on the surface of native p53 and thus most likely involved in p53 functionality are Cys176, Cys182, Cys229, Cys242, and Cys277 (31) tiary structure necessary for p53 to bind DNA in a sequence-specific fashion (4).”
The oncogenic roles of p53 mutants in mouse models
Lozano, G. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.003 · Cited by 94
Blanden, A. R., Yu, X., Wolfe, A. J., Gilleran, J. A., Augeri, D. J., O’Dell, R. S., Olson, E. C., Kimball, S. D., Emge, T. J., Movileanu, L., et al. (2015) · Molecular Pharmacology · doi:10.1124/mol.114.097550 · Cited by 79
“Each p53 monomer coordinates a single Zn 2+ via C176, C238, C242, and H179 (Cho et al. , 1994).”
BackgroundImpact of Alu repeats on the evolution of human p53 binding sites
Cui, F., Sirotin, M. V., & Zhurkin, V. B. (2011) · Biology Direct · doi:10.1186/1745-6150-6-2 · Cited by 85
“(The core motif CNNG in the center of each p53 half-site is critical for rigorous p53-DNA recognition through formation of the arginine-guanine hydrogen bonds in the major groove [62,63].”
BackgroundA role for p53 in the frequency and mechanism of mutation
Morris, S. M. (2002) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(01)00075-8 · Cited by 96
Mutant p53: Gain-of-Function Oncoproteins and Wild-Type p53 Inactivators
Roemer, K. (1999) · Biological Chemistry · doi:10.1515/bc.1999.108 · Cited by 86
“The mutants fall into two classes: class I mutants carry mutated amino acid residues that compromise DNA contact without changing the overall protein conformation; class II mutants have residues affected that are critical for the maintenance of tertiary structure (Cho et al., 1994; Prives, 1994).”
BackgroundWu, Q., Fan, C., Chen, T., et al. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.01.037 · Cited by 85
“2E), which can form a complex with CDK to regulate the progression of cells [25,26].”
BackgroundAcetylation of the DNA Binding Domain Regulates Transcription-independent Apoptosis by p53
Sykes, S. M., Stanek, T. J., Frank, A., Murphy, M. E., & McMahon, S. B. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.026096 · Cited by 85
Small molecule agents targeting the p53‐MDM2 pathway for cancer therapy
Wang, W., & Hu, Y. (2012) · Medicinal Research Reviews · doi:10.1002/med.20236 · Cited by 85
Apigenin enhances the cisplatin cytotoxic effect through p53-modulated apoptosis
Liu, R., Ji, P., Liu, B., Qiao, H., Wang, X., Zhou, L., Deng, T., & Ba, Y. (2016) · Oncology Letters · doi:10.3892/ol.2016.5495 · Cited by 90
“As a tumor suppressor, p53 has an important role in genome stability and functions as a critical tumor suppressor that is involved in preventing cancer (40).”
Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status
Mirjolet, J.-F., Barberi‐Heyob, M., Mirjolet, C., Peyrat, J.-P., Abecassis, J., Millon, R., & Merlin, J. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1455 · Cited by 92
“…residue 248 is directly involved in p53 DNA-binding, and the reduced the affinity of p53 for its consensus sites by removing c cal contact with DNA (Cho et al, 1994; Arrowsmith and Morin 1996) without changing p53 conformation (Ory et al, 1994). p mRNA basal expression was reduced in p53 mutated…”
BackgroundLane, D. P., & Hupp, T. R. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02669-2 · Cited by 99
Skaug, V., Ryberg, D., Kure, E. H., Arab, M. O., Stangeland, L. B., Myking, A. O., & Haugen, A. (2000) · PubMed · Cited by 85
Abarzúa, P., LoSardo, J. E., Gubler, M. L., & Neri, A. (1995) · PubMed · Cited by 90
Targeting Therapies for the p53 Protein in Cancer Treatments
Levine, A. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055455 · Cited by 84
“The X-ray (Cho et al. 1994) and nuclear magnetic resonance structures of the DBD ( Joerger et al. 2005) are known and show a compact structure, with several amino acids that make close contacts with DNA residues (248, 273, and 282) and a set of amino acids that are further away from the DNA and stabilize the overall s…”
BackgroundAssociation of T P53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer
Deneka, A. Y., Baca, Y., Serebriiskii, I. G., Nicolas, É., Parker, M. I., Nguyen, T. T., Xiu, J., Korn, W. M., Demeure, M. J., Wise-Draper, T. M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4316 · Cited by 101
p53 as a target for anti-cancer drug development
Bouchet, B. P., de Fromentel, C. C., Puisieux, A., & Galmarini, C. M. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.10.005 · Cited by 91
“In terms of three-dimensional structure, the DNA-binding domain is made of a scaffold of beta-sheets that supports flexible loops and helixes, which are in direct contact with DNA [5].”
BackgroundMutant Mice Lacking the p53 C-Terminal Domain Model Telomere Syndromes
Simeonova, I., Jaber, S., Draskovic, I., Bardot, B., Fang, M., Bouarich-Bourimi, R., Lejour, V., Charbonnier, L., Soudais, C., Bourdon, J.-C., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.05.028 · Cited by 83
A cationic cholesterol based nanocarrier for the delivery of p53-EGFP-C3 plasmid to cancer cells
Misra, S. K., Naz, S., Kondaiah, P., & Bhattacharya, S. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.062 · Cited by 85
Versatile functions of p53 protein in multicellular organisms
Chumakov, P. M. (2007) · Biochemistry (Moscow) · doi:10.1134/s0006297907130019 · Cited by 84
PDBSite: a database of the 3D structure of protein functional sites
Иванисенко, В. А., Pintus, S. S., Grigorovich, D. A., & Kolchanov, N. A. (2004) · Nucleic Acids Research · doi:10.1093/nar/gki105 · Cited by 86
“Mechanisms as to how tumorigenic DBD mutations undeniably cause reduction in p53 site-specific DNA-binding activity (18,19) were thought provoking: just by eliminating critical protein–DNA contact like R273H (20–22), by lowering thermodynamic stability to the level at which DBD is predicted to be for the most part unfo…”
BackgroundHSP70 Binding Sites in the Tumor Suppressor Protein p53
Fourie, A. M., Hupp, T. R., Lane, D. P., Sang, B., Barbosa, M. S., Sambrook, J., & Gething, M.-J. H. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.31.19471 · Cited by 83
Metadata
- Authors
- Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Science
- Published
- 1994-07-15
- Volume
- 265
- Issue
- 5170
- Pages
- 346-355
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2096276671
- Semantic Scholar
- 11096f3b08e172ce5e261795b6749818ee59c03d
- Cited by
- 2,551
- References
- 62
- Citations by year
- 2026: 62 · 2025: 52 · 2024: 40 · 2023: 64 · 2022: 61 · 2021: 73 · 2020: 67 · 2019: 62 · 2018: 61 · 2017: 54 · 2016: 64 · 2015: 62 · 2014: 81 · 2013: 78 · 2012: 68
- FWCI
- 64.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- National Cancer Institute (NCI CA08748-29)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- p53 tumor suppressor, p53 core domain, DNA binding, zinc coordination, beta-sandwich, cancer genetics
- MeSH terms
- Amino Acid Sequence, Base Sequence, Binding Sites, Computer Graphics, Crystallization, DNA, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Mutation, Nucleic Acid Conformation, Protein Conformation, Genes, p53, Tumor Suppressor Protein p53, Protein Structure, Secondary, Crystallography, X-Ray
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.